Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

7,361 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA, Feldman L, Seckler A, Wilson A. DiMasi JA, et al. Among authors: wilson a. Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Clin Pharmacol Ther. 2010. PMID: 20130567 Review.
Development of and access to products for neglected diseases.
Cohen J, Dibner MS, Wilson A. Cohen J, et al. Among authors: wilson a. PLoS One. 2010 May 12;5(5):e10610. doi: 10.1371/journal.pone.0010610. PLoS One. 2010. PMID: 20485552 Free PMC article.
Our objective was to reassess drug development between 1975 and 1999, evaluate progress in neglected disease drug development since 2000, and explain how increased numbers of approvals are a necessary but insufficient condition to improving access. ...Second, using the G-F …
Our objective was to reassess drug development between 1975 and 1999, evaluate progress in neglected disease drug development since 2000, an …
New challenges to medicare beneficiary access to mAbs.
Cohen J, Wilson A. Cohen J, et al. Among authors: wilson a. MAbs. 2009 Jan-Feb;1(1):56-66. doi: 10.4161/mabs.1.1.7246. MAbs. 2009. PMID: 20046575 Free PMC article. Review.
The relatively high cost of mAbs, together with the absence of a regulatory pathway to generics, stand out as distinctive economic features. ...We suggest more systematic use of "coverage with evidence development" as a means of optimally addressing these challenges …
The relatively high cost of mAbs, together with the absence of a regulatory pathway to generics, stand out as distinctive economic fe …
Clinical and economic challenges facing pharmacogenomics.
Cohen J, Wilson A, Manzolillo K. Cohen J, et al. Among authors: wilson a. Pharmacogenomics J. 2013 Aug;13(4):378-88. doi: 10.1038/tpj.2011.63. Epub 2012 Jan 10. Pharmacogenomics J. 2013. PMID: 22231566
We found that Medicare beneficiary access to physician-administered (Medicare part B) drugs is relatively unfettered, with a fixed patient co-insurance percentage of 20%. ...There is a lack of comprehensive reimbursement of companion diagnostics, even in cases in wh …
We found that Medicare beneficiary access to physician-administered (Medicare part B) drugs is relatively unfettered, with a fixed pa …
Patient access to new cancer drugs in the United States and Australia.
Wilson A, Cohen J. Wilson A, et al. Value Health. 2011 Sep-Oct;14(6):944-52. doi: 10.1016/j.jval.2011.05.004. Epub 2011 Jul 29. Value Health. 2011. PMID: 21914517
METHODS: For a set of 2000-2009 approved new molecular entities and biologics indicated for cancer, we compared patient access between US Medicare and Australian Pharmaceutical Benefits Scheme (PBS) beneficiaries. ...CONCLUSION: Our analysis points to a possible tra …
METHODS: For a set of 2000-2009 approved new molecular entities and biologics indicated for cancer, we compared patient access betwee …
Off-label use reimbursement.
Cohen J, Wilson A, Faden L. Cohen J, et al. Among authors: wilson a. Food Drug Law J. 2009;64(2):391-403. Food Drug Law J. 2009. PMID: 19999289
Updating a study published 14 years ago, presenting the results of the survey of 179 payers administering public (Medicare and Medicaid) pharmacy benefits. The focus is on payers administering pharmacy benefits in the public sector for two reasons: First, transparency; the …
Updating a study published 14 years ago, presenting the results of the survey of 179 payers administering public (Medicare and Medica …
FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?
Wilson A, Milne CP. Wilson A, et al. Food Drug Law J. 2011;66(4):569-85, ii. Food Drug Law J. 2011. PMID: 24505829
., NMEs plus new doses and formulations of drugs) approved by FDA were required to have a REMS. As the REMS program expands, there has been an increasing chorus of stakeholders who have expressed a range of concerns and criticisms about the program's impact on the h …
., NMEs plus new doses and formulations of drugs) approved by FDA were required to have a REMS. As the REMS program expands, there ha …
Coronary Artery Bypass Grafting Among Older Adults: Patterns, Outcomes, and Trends.
Olufajo OA, Wilson A, Zeineddin A, Williams M, Aziz S. Olufajo OA, et al. Among authors: wilson a. J Surg Res. 2020 Oct 14:S0022-4804(20)30542-4. doi: 10.1016/j.jss.2020.08.002. Online ahead of print. J Surg Res. 2020. PMID: 33069392
Reduced Maternal Serum Total, Free and Bioavailable Vitamin D Levels and its Association with the Risk for Postpartum Depressive Symptoms.
Pillai RR, Premkumar NR, Kattimani S, Sagili H, Wilson AB, Sharon L, Rajendiran S. Pillai RR, et al. Among authors: wilson ab. Arch Med Res. 2020 Oct 13:S0188-4409(19)30759-3. doi: 10.1016/j.arcmed.2020.10.003. Online ahead of print. Arch Med Res. 2020. PMID: 33067012
A cohort study to identify risk factors for Plasmodium falciparum infection in Burkinabe children: implications for other high burden high impact countries.
Yaro JB, Ouedraogo A, Ouedraogo ZA, Diarra A, Lankouande M, Agboraw E, Worrall E, Toe KH, Sanou A, Guelbeogo WM, Sagnon N, Ranson H, Tiono AB, Lindsay SW, Wilson AL. Yaro JB, et al. Among authors: wilson al. Malar J. 2020 Oct 16;19(1):371. doi: 10.1186/s12936-020-03443-x. Malar J. 2020. PMID: 33066799
7,361 results
Jump to page
Feedback